Amgen Reports Second Quarter 2018 Financial Results
THOUSAND OAKS, Calif., July 26, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the second quarter of 2018. Key results include: Total revenues increased 4 percent versus the second quarter of 2017 to $6.1 billion. Product sales grew 2 percent globally. New and recently launched products including Repatha® (evolocumab), KYPROLIS® (carfilzomib), Prolia® (denosumab) and XGEVA® (denosumab), showed double-digit growth. GAAP earnings per share (EPS) increased 20 percent to $3.48 driven by higher product sales, a lower tax rate and lower weighted-average shares o...
Source: Amgen News Release - July 26, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Adjuvant Denosumab Fails to Reduce Recurrences, Deaths in Early Breast Cancer
The D-CARE study found adjuvant denosumab is devoid of benefits in high-risk early breast cancer. (Source: CancerNetwork)
Source: CancerNetwork - June 11, 2018 Category: Cancer & Oncology Authors: John Schieszer Source Type: news

European Commission Approves Prolia(R) (denosumab) for Patients With Glucocorticoid-Induced Osteoporosis
Third Indication in Europe for Prolia for the Treatment of Patients at Increased Risk of Fractures THOUSAND OAKS, Calif., June 8, 2018 -- (Healthcare Sales & Marketing Network) -- Amgen (NASDAQ: AMGN) today announced that the European Commission (EC) h... Biopharmaceuticals, Regulatory Amgen, Prolia , denosumab, osteoporosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 8, 2018 Category: Pharmaceuticals Source Type: news

European Commission Approves Prolia ® (denosumab) for Patients With Glucocorticoid-Induced Osteoporosis
Third Indication in Europe for Prolia for the Treatment of Patients at Increased Risk of Fractures THOUSAND OAKS, Calif., June 8, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has approved a new indication for Prolia® (denosumab) for the treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture. The EC approval is based on the positive results of a Phase 3 study that evaluated the safety and efficacy of Prolia compared with risedronate in patients receiving glucocorticoid tre...
Source: Amgen News Release - June 8, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Denosumab subsidised by PHARMAC for osteoporosis
(Source: PharmacoEconomics and Outcomes News)
Source: PharmacoEconomics and Outcomes News - June 1, 2018 Category: Drugs & Pharmacology Source Type: news

New Denosumab Indication; Seafood & Fertility; World Thyroid Day
(MedPage Today) -- News and commentary from the endocrinology world (Source: MedPage Today Pediatrics)
Source: MedPage Today Pediatrics - May 25, 2018 Category: Pediatrics Source Type: news

FDA Approves Denosumab for Steroid-Induced Osteoporosis FDA Approves Denosumab for Steroid-Induced Osteoporosis
The US FDA has approved denosumab (Prolia, Amgen) for treatment of glucocorticoid-induced osteoporosis. European regulators recently green-lighted the same indication.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 22, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology News Alert Source Type: news

FDA Approves Prolia ® (Denosumab) For Glucocorticoid-Induced Osteoporosis
Fifth Indication for Prolia for Men and Women at High Risk of Fracture Receiving Systemic Glucocorticoid Therapy THOUSAND OAKS, Calif., May 21, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the use of Prolia® (denosumab) for the treatment of glucocorticoid-induced osteoporosis (GIOP) in men and women at high risk of fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or patients who have failed or are intolerant to other available osteoporosis therapy. This approval is based on data...
Source: Amgen News Release - May 21, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

FDA Approves Prolia (denosumab) for Glucocorticoid-Induced Osteoporosis
THOUSAND OAKS, Calif., May 21, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the use of Prolia (denosumab) for the treatment of glucocorticoid-induced osteoporosis (GIOP) in... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - May 21, 2018 Category: Drugs & Pharmacology Source Type: news

Amgen Receives Positive CHMP Opinion To Expand Use Of Prolia(R) (denosumab) To Patients With Glucocorticoid-Induced Osteoporosis
Treats Bone Loss in Patients Using Glucocorticoid Medications who are at Increased Risk of Fracture THOUSAND OAKS, Calif., April 27, 2018 -- (Healthcare Sales & Marketing Network) -- Amgen (NASDAQ: AMGN) today announced that the Committee for Medicinal... Biopharmaceuticals, Regulatory Amgen, Prolia, denosumab, Glucocorticoid-Induced, Osteoporosis (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - April 27, 2018 Category: Pharmaceuticals Source Type: news

Amgen Receives Positive CHMP Opinion To Expand Use Of Prolia ® (denosumab) To Patients With Glucocorticoid-Induced Osteoporosis
Treats Bone Loss in Patients Using Glucocorticoid Medications who are at Increased Risk of Fracture THOUSAND OAKS, Calif., April 27, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion for the marketing authorization of Prolia® (denosumab) for the treatment of bone loss associated with long-term systemic glucocorticoid therapy in adult patients at increased risk of fracture. "Today's positive opinion by the CHMP is an important step for Prolia in help...
Source: Amgen News Release - April 27, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

UAB-led study shows drug effectiveness in reducing glucocorticoid-induced bone loss
(University of Alabama at Birmingham) About one in every 100 people in the world takes glucocorticoids long term to treat immune-mediated diseases. However, glucocorticoids, such as prednisone, have a side effect -- they induce glucocorticoid-induced bone loss, causing an estimated yearly bone fracture rate of 5 percent. An alternative treatment option to the standard treatment now appears promising, according to an international study. Researchers compared the monoclonal antibody denosumab against a standard bisphosphonate. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - April 27, 2018 Category: International Medicine & Public Health Source Type: news

Amgen Reports First Quarter 2018 Financial Results
THOUSAND OAKS, Calif., April 24, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the first quarter of 2018. Key results include: Total revenues increased 2 percent versus the first quarter of 2017 to $5.6 billion. Product sales grew 3 percent globally. All new and recently launched products including Repatha® (evolocumab), KYPROLIS® (carfilzomib), Prolia® (denosumab) and XGEVA® (denosumab) showed double-digit growth. GAAP earnings per share (EPS) increased 16 percent to $3.25 driven by higher product sales, a lower tax rate and lower weighted-average shares...
Source: Amgen News Release - April 24, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Benefits, Drawbacks to Denosumab Tx in ESRD
(MedPage Today) -- High rates of treatment-related hypocalcemia (Source: MedPage Today Endocrinology)
Source: MedPage Today Endocrinology - April 12, 2018 Category: Endocrinology Source Type: news

Steroid-Induced Bone Loss Better Treated With Denosumab? Steroid-Induced Bone Loss Better Treated With Denosumab?
Denosumab found to be superior to risedronate in the treatment of steroid-induced osteoporosis at 12 months, at least in terms of BMD, among patients starting steroid therapy or those who remained on it.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - April 10, 2018 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

European Commission Approves Expanded Indication For Amgen's XGEVA ® (denosumab) For The Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma
This Approval was Based on the Largest International Trial Ever Conducted for the Prevention of Skeletal-Related Events in Multiple Myeloma Patients THOUSAND OAKS, Calif., April 2, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the European Commission (EC) has approved an expanded indication for XGEVA® (denosumab) for the prevention of skeletal-related events in adults with advanced malignancies involving bone. The indication now covers patients with bone metastases from solid tumors and those with multiple myeloma. The approval is based on data from the Phase 3 '482 study, the largest internat...
Source: Amgen News Release - April 3, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Receives Positive Opinion Expanding Use Of XGEVA(R) (denosumab) To Cover Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma In Europe
Application Based on Data From Largest International Multiple Myeloma Trial for the Prevention of Skeletal-Related Events Ever Conducted THOUSAND OAKS, Calif., Feb. 23, 2018 -- (Healthcare Sales & Marketing Network) -- Amgen (NASDAQ: AMGN) today announ... Biopharmaceuticals, Oncology, Regulatory Amgen, XGEVA, denosumab, Multiple Myeloma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - February 23, 2018 Category: Pharmaceuticals Source Type: news

Amgen Receives Positive Opinion Expanding Use Of XGEVA ® (denosumab) To Cover Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma In Europe
Application Based on Data From Largest International Multiple Myeloma Trial for the Prevention of Skeletal-Related Events Ever Conducted THOUSAND OAKS, Calif., Feb. 23, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion to expand the current indication for XGEVA® (denosumab) to cover skeletal-related events in patients with multiple myeloma. If approved, XGEVA will be indicated for the prevention of skeletal-related events in adults with advanced malignancies involving bon...
Source: Amgen News Release - February 23, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Results From Phase 3 XGEVA ® (Denosumab) Study In Patients With Multiple Myeloma Published In The Lancet Oncology
In this study, XGEVA successfully met the primary endpoint, demonstrating non-inferiority to zoledronic acid in delaying the time to first on-study skeleta... (Source: Amgen News Release)
Source: Amgen News Release - February 8, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

FDA Expands Use of Amgen's Blockbuster Drug FDA Expands Use of Amgen's Blockbuster Drug
Amgen Inc said on Friday that the U.S. Food and Drug Administration approved its drug, Xgeva, to prevent fractures in patients with multiple myeloma.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 8, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news

FDA Expands Use of Denosumab to Myeloma Patients FDA Expands Use of Denosumab to Myeloma Patients
Amgen Inc said on Friday that the U.S. Food and Drug Administration approved its drug, Xgeva, to prevent fractures in patients with multiple myeloma.FDA Approvals (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - January 8, 2018 Category: Cancer & Oncology Tags: Hematology-Oncology News Alert Source Type: news

FDA expands use of Amgen's blockbuster drug
(Reuters) - Amgen Inc said on Friday that the U.S. Food and Drug Administration approved its drug, Xgeva, to prevent fractures in patients with multiple myeloma. (Source: Reuters: Health)
Source: Reuters: Health - January 5, 2018 Category: Consumer Health News Tags: healthNews Source Type: news

FDA Approves XGEVA ® (denosumab) For The Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma
Expansion of Indication Offers Patients a New Treatment Option Approval Based on Safety and Efficacy Data From the Largest International Multiple Myeloma Clinical Trial Ever Conducted THOUSAND OAKS, Calif., Jan. 5, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for XGEVA® (denosumab) to expand the currently approved indication for the prevention of skeletal-related events in patients with bone metastases from solid tumors to include patients with multiple myeloma. The approval is based on...
Source: Amgen News Release - January 5, 2018 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

FDA Approves XGEVA(R) (denosumab) For The Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma
Expansion of Indication Offers Patients a New Treatment Option Approval Based on Safety and Efficacy Data From the Largest International Multiple Myeloma Clinical Trial Ever Conducted THOUSAND OAKS, Calif., Jan. 5, 2018 -- (Healthcare Sales & Marketi... Biopharmaceuticals, Oncology, FDA Amgen, XGEVA, denosumab, Multiple Myeloma, bone protection (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - January 5, 2018 Category: Pharmaceuticals Source Type: news

FDA Approves Xgeva (denosumab) for the Prevention of Skeletal-Related Events in Patients with Multiple Myeloma
THOUSAND OAKS, Calif., Jan. 5, 2018 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental Biologics License Application (sBLA) for Xgeva (denosumab) to expand the currently... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - January 5, 2018 Category: Drugs & Pharmacology Source Type: news

NAMS 2017 Annual Meeting Overview NAMS 2017 Annual Meeting Overview
Drug holidays should not be taken when using denosumab; molecular breast imaging may outperform mammography; and other topics, as reviewed during the NAMS annual meeting.Medscape Ob/Gyn (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - November 8, 2017 Category: Consumer Health News Tags: Ob/Gyn & Women ' s Health Commentary Source Type: news

Generic vs Brand Bone Drug for Breast Cancer, Skeletal Mets Generic vs Brand Bone Drug for Breast Cancer, Skeletal Mets
Monthly denosumab more effective than zoledronic acid in delaying time to first skeletal-related events but over 2 years cost almost $350K more.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - October 18, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Confusion about long-term treatment of osteoporosis clarified
(The North American Menopause Society (NAMS)) Osteoporosis is a common disorder among postmenopausal women which results in an increased risk of fractures. While several therapies improve bone strength and reduce the risk of spine and hip fracture, there is no cure for osteoporosis, and long-term treatment is needed. An upcoming presentation at The North American Menopause Society (NAMS) Annual Meeting in Philadelphia Oct. 11-14 is scheduled to present new evidence about the long-term effectiveness and safety of treatment with bisphosphonates and denosumab. (Source: EurekAlert! - Social and Behavioral Science)
Source: EurekAlert! - Social and Behavioral Science - October 11, 2017 Category: International Medicine & Public Health Source Type: news

FDA Accepts Supplemental Biologics License Application For Prolia ® (Denosumab) In Glucocorticoid-Induced Osteoporosis
Glucocorticoid-Induced Osteoporosis is the Most Common Form of Secondary Osteoporosis THOUSAND OAKS, Calif., Oct. 9, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for Prolia® (denosumab) for the treatment of patients with glucocorticoid-induced osteoporosis (GIOP). The sBLA, which was submitted on July 28, 2017, is based on a Phase 3 study evaluating Prolia compared with risedronate in patients receiving glucocorticoid treatment. The FDA has set a Prescription Drug User Fee Act ...
Source: Amgen News Release - October 9, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Highlights The Latest EVENITY ™ (Romosozumab) And Prolia® (Denosumab) Research At The American Society For Bone And Mineral Research Annual Meeting
First Presentation of Detailed EVENITY ARCH Study Results and FRAME Extension Final Analysis 10-Year Data From Long-Term Prolia FREEDOM Study THOUSAND OAKS, Calif., Sept. 8, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that 19 scientific abstracts will highlight the latest scientific research on EVENITY™* (romosozumab) and Prolia® (denosumab) at this year's Annual Meeting of the American Society for Bone and Mineral Research (ASBMR) in Denver from Sept. 8-11, 2017. "The data being presented at ASBMR underscore our steadfast focus for more than a decade to advance scientific unders...
Source: Amgen News Release - September 8, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Prostate Cancer Patients Can Improve Bone Health With Osteoporosis Medications
Men with non-metastatic prostate cancer who receive androgen deprivation therapy risk loss of bone mineral density and fractures, but both bisphosphonates and denosumab can improve their bone health. (Source: CancerNetwork)
Source: CancerNetwork - August 8, 2017 Category: Cancer & Oncology Authors: Mark L. Fuerst Tags: Genitourinary Cancers News Prostate Cancer Source Type: news

Osteoporosis medications improve bone health in men being treated for prostate cancer
(American College of Physicians) Both biophosphonates and denosumab improve bone mineral density in men with nonmetastatic prostate cancer who are receiving androgen deprivation therapy. The results from a systematic review and meta-analysis are published in Annals of Internal Medicine. (Source: EurekAlert! - Cancer)
Source: EurekAlert! - Cancer - August 7, 2017 Category: Cancer & Oncology Source Type: news

Single Shot of Zoledronate Doesn't Preserve BMD After Denosumab Single Shot of Zoledronate Doesn't Preserve BMD After Denosumab
A single dose of zoledronate does not adequately preserve bone mineral density gains seen with long-term denosumab treatment, once the latter is discontinued.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - August 4, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Bone loss after denosumab, only partial protection with zoledronate
This report investigates whether a single infusion of zoledronate might also be an effective option to prevent bone loss after long-term denosumab treatment in postmenopausal patients is discontinued. (Source: EurekAlert! - Medicine and Health)
Source: EurekAlert! - Medicine and Health - August 2, 2017 Category: International Medicine & Public Health Source Type: news

Amgen Submits Supplemental Biologics License Application For Prolia ® (denosumab) In Glucocorticoid-Induced Osteoporosis
THOUSAND OAKS, Calif., July 31, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) for Prolia® (denosumab) for the treatment of patients with glucocorticoid-induced osteoporosis (GIOP).The sBLA is based on a Phase 3 study evaluating the safety and efficacy of Prolia compared with risedronate in patients receiving glucocorticoid treatment. Osteoporosis can be caused by glucocorticoid medications, which are prescribed to treat inflammatory diseases. Within the first three months of beginning ...
Source: Amgen News Release - July 31, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Reports Second Quarter 2017 Financial Results
THOUSAND OAKS, Calif., July 25, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced financial results for the second quarter of 2017. Key results include: Total revenues increased 2 percent versus the second quarter of 2016 to $5.8 billion. Product sales grew 2 percent driven by Prolia® (denosumab), Repatha® (evolocumab) and KYPROLIS® (carfilzomib). GAAP earnings per share (EPS) increased 18 percent to $2.91 driven by higher operating margins. GAAP operating income increased 13 percent to $2.7 billion and GAAP operating margin increased 4.9 percentage points to 48.4 percent. N...
Source: Amgen News Release - July 25, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Denosumab Shows Benefits in Multiple Myeloma Bone Disease Denosumab Shows Benefits in Multiple Myeloma Bone Disease
In a head-to-head comparison with zoledronic acid, denosumab was noninferior, with prolonged time to a first skeletal event and a reduced risk for renal events.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - June 27, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news

Amgen To Present New Data At 22nd Congress of the European Hematology Association
Oral Presentation of Phase 3 Data Shows KYPROLIS® (Carfilzomib) and Dexamethasone Improved Median Overall Survival by 7.6 Months Compared to Velcade® (Bortezomib) and Dexamethasone in Relapsed Multiple Myeloma New Subset Analysis Demonstrates BLINCYTO® (Blinatumomab) More Than Doubled Median Overall Survival Versus Standard of Care Chemotherapy in Adult Patients With Relapsed/Refractory Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia in First Salvage Oral Presentation of New Data From Head-to-Head Phase 3 Study of XGEVA® (Denosumab) Versus Zoledronic Acid in Time to First On-Study Skeletal...
Source: Amgen News Release - June 21, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

FDA Accepts Amgen's Supplemental Biologics License Application To Expand Indication For XGEVA(R) (denosumab) To Include Multiple Myeloma Patients
FDA Sets PDUFA Target Action Date of Feb. 3, 2018 THOUSAND OAKS, Calif., June 19, 2017 -- (Healthcare Sales & Marketing Network) -- Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted the XGEVA® (denos... Biopharmaceuticals, Oncology, FDA Amgen, XGEVA, denosumab, Multiple Myeloma (Source: HSMN NewsFeed)
Source: HSMN NewsFeed - June 19, 2017 Category: Pharmaceuticals Source Type: news

FDA Accepts Amgen's Supplemental Biologics License Application To Expand Indication For XGEVA ® (denosumab) To Include Multiple Myeloma Patients
FDA Sets PDUFA Target Action Date of Feb. 3, 2018 THOUSAND OAKS, Calif., June 19, 2017 /PRNewswire/ -- Amgen (NASDAQ: AMGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted the XGEVA® (denosumab) supplemental Biologics License Application (sBLA) that seeks to expand the currently approved indication for the prevention of fractures and other skeletal-related events in patients with bone metastases from solid tumors to include patients with multiple myeloma. The FDA has set a Prescription Drug User Fee Act (PDUFA) action date of Feb. 3, 2018. "Multiple mye...
Source: Amgen News Release - June 19, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Amgen Presents New Data From Phase 3 XGEVA ® (Denosumab) Study In Patients With Multiple Myeloma At ASCO 2017
Analysis Demonstrated XGEVA had a Significantly Lower Rate of Renal Adverse Events Compared to Zoledronic Acid Data Selected for Best of ASCO® Educational Program THOUSAND OAKS, Calif., June 4, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced new data from the XGEVA® (denosumab) Phase 3 '482 study, the largest international multiple myeloma trial ever conducted. The study met its primary endpoint, demonstrating XGEVA is non-inferior to zoledronic acid in delaying the time to first on-study skeletal-related event in patients with multiple myeloma (HR=0.98, 95 percent CI: 0.85, 1.14; p=0.01). The ...
Source: Amgen News Release - June 4, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Comparison of osteoporosis treatments for improving bone mineral density
After teriparatide, osteoporosis treatment with denosumab yields higher additional bone mineral density gain, compared with bisphosphonates, according to data presented at the European Congress of Endocrinology 2017.Medscape (Source: Society for Endocrinology)
Source: Society for Endocrinology - May 31, 2017 Category: Endocrinology Source Type: news

Denosumab Ups BMD More Than Bisphosphates After Teriparatide Denosumab Ups BMD More Than Bisphosphates After Teriparatide
Use of denosumab after stopping teriparatide yields a greater increase in bone-mineral density in postmenopausal women with severe osteoporosis than bisphosphonates, according to a retrospective analysis.Medscape Medical News (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - May 25, 2017 Category: Consumer Health News Tags: Diabetes & Endocrinology News Source Type: news

Amgen Highlights Data To Be Presented At ASCO 2017 Across Oncology Portfolio
Oral Presentation of New Analysis on Limited Renal Toxicity Associated With XGEVA® (denosumab) Compared With Zoledronic Acid in Treatment of Myeloma Bone Disease XGEVA Study in Patients With Myeloma Bone Disease Also Selected for Best of ASCO® First Randomized Study to Evaluate the Combination of IMLYGIC® (talimogene laherparepvec), an Oncolytic Viral Immunotherapy, With a Checkpoint Inhibitor to be Presented THOUSAND OAKS, Calif., May 17, 2017 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that new clinical data and analyses from across its oncology portfolio will be presented at the 53rd An...
Source: Amgen News Release - May 17, 2017 Category: Pharmaceuticals Tags: Uncategorized Source Type: news

Medical News Today: Osteoporosis: ACP update treatment guidelines for preventing bone fractures
In revised guidelines, the ACP strongly advise that women with osteoporosis should be treated with bisphosphonates or denosumab to prevent bone fractures. (Source: Health News from Medical News Today)
Source: Health News from Medical News Today - May 9, 2017 Category: Consumer Health News Tags: Bones / Orthopedics Source Type: news

ACP Updates Guidelines on Treating Low Bone Density, Osteoporosis (FREE)
By Amy Orciari Herman Edited by David G. Fairchild, MD, MPH, and Jaye Elizabeth Hefner, MD Clinicians should offer alendronate, risedronate, zoledronic acid, or denosumab to women with osteoporosis to reduce the risk for hip and vertebral fractures (strong … (Source: Physician's First Watch current issue)
Source: Physician's First Watch current issue - May 9, 2017 Category: Primary Care Source Type: news